LYR-210 & Nasal Polyps: Promising CRSwNP Treatment
- Lyra Therapeutics' LYR-210, an investigational treatment for chronic rhinosinusitis (CRS), has demonstrated positive results in the ENLIGHTEN 2 phase 3 clinical trial.
- The trial focused on a composite of three cardinal symptoms (3CS) of CRS: nasal obstruction, nasal discharge, and facial pain or pressure.
- Zachary Soler, professor at the Medical University of South Carolina and lead investigator, emphasized the potential impact."The positive results seen...
LYR-210, a promising investigational treatment, is showing significant advancements for chronic rhinosinusitis (CRS) patients. The ENLIGHTEN 2 phase 3 clinical trial revealed positive results, with LYR-210 meeting its primary endpoint by improving key CRS symptoms such as nasal obstruction, discharge, and facial pain. This potential breakthrough offers a novel approach, providing six months of continuous anti-inflammatory therapy with a single administration.Patients with and without nasal polyps may benefit from this long-acting implantable corticosteroid matrix. News Directory 3 is following the story. What’s next for this innovative treatment of chronic sinusitis?
LYR-210 Shows Promise for Chronic Rhinosinusitis Treatment
Updated June 5, 2025
Lyra Therapeutics’ LYR-210, an investigational treatment for chronic rhinosinusitis (CRS), has demonstrated positive results in the ENLIGHTEN 2 phase 3 clinical trial. The study, detailed in a recent news release, met its primary endpoint by showing significant improvement in key CRS symptoms.
The trial focused on a composite of three cardinal symptoms (3CS) of CRS: nasal obstruction, nasal discharge, and facial pain or pressure. Patients treated with LYR-210 experienced notable relief at week 24, suggesting a potential breakthrough in chronic sinusitis management.
dr. Zachary Soler, professor at the Medical University of South Carolina and lead investigator, emphasized the potential impact.”The positive results seen… are impressive and represent what could be a promising new treatment approach for the many CRS patients…who are underserved by limited therapies,” Soler said.
Chronic rhinosinusitis, or chronic sinusitis, involves inflammation of the sinus lining. While the exact cause remains unclear, it’s believed to stem from an immune system overreaction. Common symptoms include facial pain, post-nasal drip, and thick nasal mucus. LYR-210 offers a new approach by delivering continuous anti-inflammatory therapy directly to the sinonasal passages.
LYR-210 is designed as a bioabsorbable nasal implant containing mometasone furoate. It is intended to provide six months of continuous anti-inflammatory treatment following a simple in-office insertion.
Maria Palasis, PhD, president and CEO of Lyra Therapeutics, highlighted the potential of LYR-210. “We believe this has the potential to provide a path to advance LYR-210 to treat CRS, offering 6 months of therapy in a single administration for millions of patients who do not respond to standard CRS medical management,” Palasis said.
The ENLIGHTEN program includes two phase 3 trials, ENLIGHTEN 1 and ENLIGHTEN 2, evaluating LYR-210’s effectiveness and safety. While ENLIGHTEN 2 achieved its primary goals, ENLIGHTEN 1 did not meet its primary or secondary endpoints, according to reports from May 2024.
Both trials enrolled 180 CRS patients who hadn’t responded to medical management and hadn’t undergone previous ethmoid sinus surgery. Participants were randomly assigned to receive LYR-210 or a sham control. The primary endpoint, assessed at 24 weeks, focused on LYR-210’s long-acting therapeutic effect.
The ENLIGHTEN 2 trial demonstrated statistically significant improvement in the 3CS of CRS at week 24 among individuals without nasal polyps (P = 0.0078). The study also showed significant improvements in 3CS for the entire patient population (P = 0.0209) and clinically meaningful improvements in SNOT-22 scores as early as week 4 (P = 0.0456).
“The more than 20-point improvement from baseline in SNOT-22 score after LYR-210 treatment represents a clinically meaningful improvement in patient symptoms,” said Dr. Soler.
A combined analysis of 64 CRS patients with grade 1 nasal polyps from both trials showed consistent positive trends for LYR-210 over 24 weeks.
“Looking further ahead, we envision LYR-210 achieving its potential to benefit both non-polyp and polyp patients, positioning us to become a leader in CRS and validating our platform for future ENT indications,” Palasis concluded.
What’s next
Lyra Therapeutics plans to continue evaluating the data from the ENLIGHTEN 2 trial and work toward potential regulatory submissions for LYR-210 as a treatment for chronic rhinosinusitis.